Cell Source Appoints Dr. Hermann Einsele to Its Scientific Advisory Board

NEW YORK, NY -- (Marketwired) -- 09/02/15 -- Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Hermann Einsele, Professor of Internal Medicine and Director of the Department of Internal Medicine of the Julius Maximilian University, Würzburg, Germany, has joined its Scientific Advisory Board.

Itamar Shimrat, CEO of Cell Source stated, "Dr. Einsele has been a close supporter of Cell Source since its inception, and we are pleased and proud to have him join our Scientific Advisory Board. His close familiarity with our technology and extensive expertise in immunotherapy for cancer make him an excellent addition to our team. He is one of the top experts in the world in multiple myeloma and stem cell transplantation, whose research is focused on adoptive immunotherapy. Dr. Einsele is passionate about the potential of our technology to save lives and eager to help bring our product to the clinic in Germany and around the world."

Dr. Einsele stated, "I have enthusiastically followed the development of Dr. Reisner's discoveries and believe that these treatments have the potential to significantly improve survival rates and quality of life for many patients." Dr. Einsele trained in Germany and the UK, and was a Research Fellow in the Department of Hematology, Oncology, Rheumatology, and Immunology at the University of Tübingen, Germany. A former visiting professor at both the Fred Hutchinson Cancer Research Center in Seattle, WA and at the City of Hope Hospital in Duarte, CA, Professor Einsele is a member of the American Society of Hematology (ASH) as well as the European Hematology Association (EHA).

Dr. Einsele is the Chairman of the German Study Group on Multiple Myeloma and serves on the Board of Directors of both the German Society of Blood and Marrow Stem Cell Transplantation and the German Lymphoma Group. He is part of the working group for Infectious Disease, Chronic Leukemia and Immunobiology at the European Group for Blood and Marrow Transplantation (EBMT). A past recipient of the van Bekkum Award, the highest annual European award for research in the field of stem cell transplantation, he is an Honorary Fellow of the Royal College of Pathologists (London), and was the 2012 Nobel Lecturer on Stem Cell Biology/Transplantation at the Nobel Forum, Karolinska Institute (Sweden).

About Cell Source, Inc.

Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine.
For more information go to www.cell-source.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on March 13, 2015. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Phone: +1 (646) 612-7554
Toll Free: +1 (888)-315-4650
Email: info@cell-source.com

Source: Cell Source, Inc.